SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• SAB Biotherapeutics has a consensus analyst rating of “Moderate Buy” from 11 covering firms, with nine buy ratings, one hold, and one sell. The average 12-month price target is $12.00.
• The stock was trading up 1.1% at $3.66, giving the company a market cap of about $279.8 million. It has ranged from $1.85 to $6.60 over the past year.
• In its latest earnings report, SAB Biotherapeutics posted a loss of $0.35 per share, missing analyst estimates of a $0.20 loss. Analysts currently expect the company to report -1.19 EPS for the full fiscal year.

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $12.00.

A number of research analysts recently weighed in on the company. Zacks Research raised SAB Biotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, May 11th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Jefferies Financial Group started coverage on SAB Biotherapeutics in a report on Wednesday, May 20th. They set a "buy" rating and a $11.00 price target for the company. Weiss Ratings reiterated a "sell (d+)" rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Finally, Citigroup began coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a "buy" rating and a $11.00 price objective on the stock.

SAB Biotherapeutics Trading Up 1.1%

NASDAQ:SABS opened at $3.66 on Friday. The firm has a market capitalization of $279.84 million, a P/E ratio of -1.73 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics has a one year low of $1.85 and a one year high of $6.60. The company's 50-day simple moving average is $3.72 and its 200 day simple moving average is $3.85.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.15). As a group, analysts forecast that SAB Biotherapeutics will post -1.19 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. bought a new stake in shares of SAB Biotherapeutics during the first quarter valued at approximately $29,000. State of Wyoming purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $34,000. ADAR1 Capital Management LLC boosted its stake in SAB Biotherapeutics by 75.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company's stock valued at $99,000 after purchasing an additional 11,344 shares during the last quarter. State Street Corp bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth $49,000. Finally, Fifth Lane Capital LP bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth $56,000. Hedge funds and other institutional investors own 7.82% of the company's stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.